Scientific publications

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

Oct 14, 2016 | Magazine: Annals of Hematology

Mateos MV (1), Oriol A (2), Martínez-López J (3), Teruel AI (4), Bengoechea E (5), Palomera L (6), de Arriba F (7), Esseltine DL (8), Cakana A (9), Pei L (10), van de Velde H (8), Miguel JS (11).
(1) Servicio de Hematología, Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Paseo San Vicente 58-182, Salamanca, 37007, Spain. 
(2) Clinical Hematology Service and Oncohematological Clinical Trial Unit of the Institut Català d'Oncologia (ICO), Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras (IJC), Barcelona, Spain.
(3) Hospital Universitario 12 de Octubre, S de Hematología HUNET-CRIS Unidad Ensayos Tempranos, Madrid, Spain.
(4) Hospital Clínico Universitario de Valencia, Servicio de Hematología, Valencia, Spain.
(5) Hospital de Donostia, Servicio de Hematología, Paseo Dr. Beguiristain 115, 20014, Donostia - San Sebastian (Guipúzcoa), Spain.
(6) Servicio de Hematología, Hospital Clínico Universitario "Lozano Blesa" Zaragoza, Instituto de Investigación Sanitaria (ISS) de Aragón, Zaragoza, Spain.
(7) Servicio de Hematología y Hemoterapia, Hospital General Universitario Morales Meseguer, Murcia, Spain.
(8) Oncology Clinical Research, Millennium Pharmaceuticals, Inc, Cambridge, MA, USA.
(9) Janssen Research & Development, High Wycombe, United Kingdom.
(10) Janssen Research & Development, LLC, Raritan, NJ, USA.
(11) Department of Hematology, Clinica Universidad de Navarra-CIMA-IDSINA, Pamplona, Spain. 


Bortezomib-melphalan-prednisone (VMP) is a standard-of-care for previously untreated, transplant-ineligible multiple myeloma (MM).

Here, we compared outcomes between VMP regimens in the VISTA trial (9-cycle VMP schedule, including 4 cycles of twice weekly bortezomib) and the PETHEMA/GEM05 trial (less intensive 6-cycle VMP schedule with 1 cycle of twice weekly and 5 cycles of weekly bortezomib, then bortezomib-based maintenance).

A total of 113 patient pairs matched by propensity score (estimated using logistic regression and incorporating eight exposure/outcome-related parameters) were included in this retrospective analysis. Median cumulative bortezomib dose was higher in PETHEMA/GEM05 than VISTA (49.6 vs 37.0 mg/m2); median dose intensity was lower (2.0 vs 5.1 mg/m2/month). Median progression-free survival (PFS) and time-to-progression (TTP) were significantly longer in PETHEMA/GEM05 than VISTA (PFS, 30.5 vs 20.0 months, p = 0.0265; TTP, 33.8 vs 24.2 months, p = 0.0049) after a median follow-up of 77.2 and 26.0 months, respectively.

Median overall survival (OS) was similar (61.3 vs 61.0 months, p = 0.6528; median follow-up, 77.6 vs 60.1 months). Post-induction complete response rate was lower in PETHEMA/GEM05 than VISTA (19 vs 31 %; p = 0.03318); on-study (including maintenance) rate was similar (30 vs 31 %; p = 0.89437).

This analysis suggests that the less-intensive PETHEMA/GEM05 VMP regimen plus maintenance may improve PFS and TTP, but not OS, compared with the VISTA VMP regimen.

CITATION  Ann Hematol. 2016 Oct 14.

Our authors

Navarre headquarters
Madrid headquarters